Recent Updates
Recently added Catalysts

Gastric Cancer: 8 biotech companies competing in the clinic

OncologyKnife fightData as of 2026-09-04

Competitors8in the clinic
Median market cap$575Muniverse median $1.20B
Allocated capital$3.6B$26.0B competing
Phase 3 or filed22 mid, 4 early
Pure plays0this indication only
Capital rank50/299crowding rank 17

Gastric Cancer is one of the more crowded fields on the map: 8 companies in the clinic, ranking it 17th of 299 indications by competitor count. The median competitor is worth $575M, below the $1.20B median of the universe.

That gap is the crowding discount. When a field is deep the market pays less per company, because the same eventual revenue has to be split across more shots on goal.

JAZZ carries 62% of the $26.0B competing here, more than the other 7 companies combined.

$3.6B of allocated capital sits in Gastric Cancer, ranking it 50th of 299 indications by the money committed to it.

Companies developing drugs for Gastric Cancer 8

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
JAZZJazz PharmaceuticalsZanidatamabPhase 31$16.1BNo14 30 Sep 2026
AGENAgenusBotensilimabPhase 32$371MNo7 31 Dec 2026
VSTMVerastemAvutometinibPhase 22$723MNo8 31 Dec 2026
ALXOALX Oncology HoldingsEvorpaceptPhase 22$281MNo4 31 Dec 2026
LEGNLegend BiotechLB1908Phase 11$4.0BNo3No dated event
TNGXTango TherapeuticsS095029Phase 11$3.8BNo5 23 Oct 2026
CMPXCompass TherapeuticsCTX-10726Phase 11$427MNo3 24 Oct 2026
DTILPrecision BioSciencesCEA-targeted CAR-T cellsPhase 13$203MNo16 31 Dec 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile. JAZZ holds 62% of the $26.0B competing in this indication.

Why Gastric Cancer is a knife fight

Crowded and cheaply priced. Six or more competitors and a median company below the universe median.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Gastric Cancer has 8 competitors and a median of $575M.

Oncology

Oncology holds $187B of the map's capital, 27.8% of the total, spread across 119 indications and 103 companies. 34 of those indications have more than one company competing.

See every Oncology indication on the map

Related indications in Oncology

Chronic Lymphocytic Leukemia4 companies · $3.7B · median $2.1BConcentrated betRenal Cell Carcinoma5 companies · $3.4B · median $3.8BConcentrated betHER2 Positive Breast Cancer2 companies · $3.3B · median $10.2BConcentrated betBladder Cancer with FGFR3 Mutation1 company · $3.3B · median $6.6BUncontestedGlioblastoma6 companies · $3.0B · median $432MKnife fightMetastatic Castration Resistant Prostate Cancer3 companies · $2.8B · median $4.0BConcentrated betWell-differentiated Non-functional Neuroendocrine Tumor1 company · $4.5B · median $9.0BUncontestedNon-Squamous Non-Small Cell Lung Cancer1 company · $2.7B · median $13.7BUncontested

Gastric Cancer pipeline questions

Which biotech companies are developing drugs for Gastric Cancer?

8 US-listed companies in the $100M to $20B market cap band run clinical programmes in Gastric Cancer. The largest and most advanced are Jazz Pharmaceuticals (JAZZ, Zanidatamab, Phase 3); Agenus (AGEN, Botensilimab, Phase 3); Verastem (VSTM, Avutometinib, Phase 2); ALX Oncology Holdings (ALXO, Evorpacept, Phase 2); Legend Biotech (LEGN, LB1908, Phase 1). The full list of 8 is in the table on this page.

How advanced is the Gastric Cancer pipeline?

Of the 8 clinical-stage programmes in Gastric Cancer, 2 are in Phase 3 or filed, 2 are in mid-stage development and 4 are in early-stage development.

Which company leads the Gastric Cancer field?

JAZZ is the largest developer in Gastric Cancer, holding 62% of the $26.0B of market capitalisation competing in the indication. The median competitor is worth $575M.

When is the next Gastric Cancer catalyst?

The next dated catalyst in Gastric Cancer is JAZZ on 30 Sep 2026. 7 dated events across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map